Hi, I’m opening a small private beta for a new PDUFA Pulse-adjacent product.

It’s called Biotech Dealmaker Brief.

The idea is simple:

PDUFA Pulse tracks biotech/FDA catalyst events.

Biotech Dealmaker Brief asks what those events change for deal pricing.

It is built for people who price, source, structure, or evaluate biotech transactions: BD, corp dev, licensing, sell-side biotech banking/advisory, biotech investors, founders, and operators.

It is not a stock-picking note.
It is not a probability-of-approval product.
It is not general biotech news.

Each issue turns resolved biotech events, approvals, readouts, CHMP/FDA actions, deal announcements, IP events, SEC filings, into a weekly BD committee prep pack:

  • board-ready summary

  • comp / leverage reset

  • top deal-pricing events

  • deal-structure watchouts

  • outreach / screening priorities

  • precedent table

  • mispricing flag where applicable

Sample issue here:

I’m looking for a small first group to receive the brief free for 4 weeks and give direct feedback on whether it is useful, what should change, and whether this is worth building into a paid product.

Request beta access:
https://tally.so/r/A7jYOB

If you work in or around biotech BD, corp dev, licensing, investing, banking/advisory, or asset evaluation, I’d especially value your feedback.

Thanks,
Richard
PDUFA Pulse

Keep Reading